The Learning Podcast, hosted by Roupen, thoroughly examines the treatment protocol for metastatic non-small cell lung cancer, focusing on in-depth discussions about first and second-line treatment methods. Roupen clearly explains that the first-line treatment depends on individual patients' specific genetic alterations and the expression level of programmed death-ligand 1 (PD-L1). The podcast further details specific treatments such as osimertinib, alectinib, crizotinib, pembrolizumab, and chemotherapy combinations. In cases of unsuccessful first-line treatment, Roupen delves into the second-line treatments, mentioning docetaxel and chemotherapeutic agents based on the patient's previous treatments and histology. The session concludes with an invitation for listener feedback and a reminder to consult the show notes for references to various studies and articles.